Intratumoral Drug Distribution in Solid Tumors

Abstract

Intratumoral drug distribution is a major determinant of therapeutic response in solid tumors and a critical limitation of systemic anticancer treatment. Although a drug may achieve adequate plasma exposure, delivery to malignant tissue can remain heterogeneous because of abnormal vasculature, elevated interstitial fluid pressure, dense extracellular matrix, cellular packing, necrosis, and variable expression of transport and binding determinants. These barriers create spatial differences in drug concentration that may allow resistant cellular subpopulations to survive despite apparently appropriate dosing. This review summarizes the biological mechanisms governing intratumoral distribution, the clinical consequences of inadequate penetration, current diagnostic and pharmacologic strategies, and emerging approaches designed to improve spatial drug delivery. Particular attention is given to nanoparticle systems, antibody–drug conjugates, local administration, tumor microenvironment modification, image-guided delivery, and quantitative pharmacology. A clinically useful framework requires integration of systemic pharmacokinetics, tumor physiology, tissue penetration, intracellular activity, and treatment-related toxicity. Improved distribution assessment and mechanism-based selection of therapies may enhance response durability while reducing ineffective exposure.

Introduction

Solid tumors are not pharmacologically uniform tissues. They contain malignant cells, stromal fibroblasts, endothelial cells, immune populations, extracellular matrix, necrotic regions, and fluid compartments that differ substantially in perfusion, oxygenation, acidity, and drug accessibility. Consequently, the concentration measured in plasma or even in a whole-tumor homogenate may not reflect the concentration experienced by individual cancer cells. Intratumoral drug distribution describes the movement and spatial organization of a therapeutic agent within tumor tissue, including vascular delivery, extravasation, interstitial transport, cellular uptake, intracellular localization, metabolism, and removal.

For clinicians, this issue explains why favorable systemic pharmacokinetics do not always translate into tumor response. A drug can have a long circulating half-life but limited penetration into poorly perfused regions. Conversely, highly diffusible agents may enter tumors effectively but produce dose-limiting toxicity before sustained intracellular concentrations are achieved. Distribution is therefore linked to pharmacodynamics, resistance, treatment scheduling, and the selection of combination therapy. Modern drug development increasingly evaluates tissue exposure, spatial heterogeneity, and target engagement rather than relying solely on plasma concentration and conventional response end points.

Epidemiology / Disease Burden

Solid tumors account for most cancer-related morbidity and mortality worldwide, and inadequate drug delivery contributes to treatment failure across carcinomas, sarcomas, gliomas, and metastatic disease. Distribution barriers are particularly important in pancreatic, brain, ovarian, prostate, and desmoplastic breast tumors, although the magnitude of the problem varies between patients and across lesions in the same patient. Metastases may also exhibit distinct vascularity and stromal architecture compared with the primary tumor, producing discordant exposure and response.

The burden is clinically evident in partial responses, mixed responses, early progression, and the persistence of viable tumor cells adjacent to necrotic or hypovascular areas. Heterogeneous exposure can select for resistant clones and may promote adaptation through altered DNA repair, stress signaling, epithelial–mesenchymal transition, or metabolic reprogramming. As cancer treatment becomes increasingly molecularly targeted, precise delivery to the cells expressing the relevant target is essential. The economic burden is also considerable because ineffective treatment cycles expose patients to toxicity and cost without providing meaningful disease control.

Pathophysiology

Tumor vessels are frequently tortuous, dilated, fragile, and irregularly distributed. Endothelial junction abnormalities can increase vascular permeability, but the resulting extravasation is not necessarily efficient because blood flow is heterogeneous and compression of vessels by proliferating cells and stromal matrix may cause regional hypoperfusion. The classical enhanced permeability and retention effect is therefore variable in human tumors and should not be assumed to occur uniformly. Convective transport is further reduced when elevated interstitial fluid pressure limits the pressure gradient from vessels into the tumor interstitium.

After leaving the circulation, molecules move through extracellular spaces by diffusion and, in some circumstances, convection. Large antibodies and nanoparticles generally penetrate more slowly and remain closer to vessels, whereas small molecules may diffuse farther but can be rapidly cleared or metabolized. Binding-site barriers occur when a high-affinity agent binds strongly to perivascular targets and is consumed before reaching deeper tissue. Dense collagen, hyaluronic acid, and proteoglycan networks increase diffusion resistance and may physically compress microvessels. Necrotic zones lack viable target cells but can influence pressure, acidity, and fluid movement in adjacent regions.

Cellular uptake is also decisive. Membrane transporters, receptor density, endocytosis, lysosomal sequestration, drug efflux pumps, intracellular pH, and enzymatic activation determine whether tissue exposure becomes biologically effective exposure. A drug may be present in the tumor yet fail to reach the nucleus, mitochondria, or other required intracellular compartment. These mechanisms establish a multistep distribution cascade in which failure at any stage can reduce efficacy.

Risk Factors

Patient- and tumor-level risk factors for poor distribution include large tumor volume, high stromal content, extensive fibrosis, low microvascular density, elevated interstitial pressure, hypoxia, necrosis, and rapid cellular proliferation. Anatomical location influences perfusion and the feasibility of local delivery. Prior radiation, surgery, antiangiogenic treatment, and repeated systemic therapy may remodel vessels and extracellular matrix, sometimes improving penetration but sometimes worsening vascular rarefaction and hypoxia.

Pharmacologic risk factors include excessive molecular size, high plasma protein binding, limited membrane permeability, strong nonspecific tissue binding, rapid systemic clearance, and inadequate exposure duration. Patient characteristics such as renal or hepatic dysfunction may alter the balance between exposure and toxicity, limiting the dose that can be safely administered. Interpatient variation in tumor perfusion and target expression means that a standardized dose does not produce standardized intratumoral concentrations.

Clinical Features

Intratumoral distribution failure has no pathognomonic clinical presentation. It may appear as a lack of response despite target expression, heterogeneous radiographic regression, early regrowth in previously treated areas, or progression in one lesion while other lesions remain controlled. A patient may experience systemic adverse effects indicating substantial exposure while the tumor receives insufficient therapeutic concentrations. In some settings, recurrent disease in a poorly perfused anatomical compartment suggests an important delivery limitation, although such an interpretation must be distinguished from clonal resistance.

Clinical manifestations also depend on spatial scale. Microscopic underexposure may sustain residual disease, whereas macroscopic heterogeneity can produce mixed imaging responses. In brain tumors, the blood–brain tumor barrier and variable disruption of the blood–brain barrier create regional differences in penetration. In peritoneal malignancies, free drug distribution may be favorable near treated surfaces but inadequate in deeper implants. These patterns reinforce the need to interpret clinical response alongside tumor biology and treatment exposure.

Diagnosis

Assessment of intratumoral distribution requires complementary methods. Dynamic contrast-enhanced magnetic resonance imaging and computed tomography can estimate perfusion, permeability, and extracellular volume, but these are indirect surrogates rather than direct measures of drug concentration. Positron emission tomography using radiolabeled therapeutic analogues or labeled antibodies can provide whole-body information about lesion uptake, although tracer behavior may differ from that of the active drug. Diffusion-weighted imaging and functional imaging may help identify cellularity, necrosis, and treatment-related changes.

Direct methods include paired plasma and tumor sampling, microdialysis, tissue mass spectrometry, autoradiography, fluorescence imaging, and matrix-assisted laser desorption or other spatially resolved analytical techniques. These approaches can reveal concentration gradients and drug metabolites at cellular or subcellular resolution. Their limitations include sampling error, invasiveness, temporal constraints, and difficulty distinguishing pharmacologically active free drug from total tissue-associated drug. Biopsy interpretation should therefore incorporate sampling location, tumor heterogeneity, timing relative to administration, and target engagement biomarkers.

Treatment & Management

Management begins with selecting an agent whose physicochemical properties match the tumor barrier profile. Small, moderately lipophilic molecules may penetrate dense tissue more effectively, whereas biologics may require receptor-mediated transport, optimized affinity, or engineering to reduce perivascular trapping. Dose and schedule influence distribution: repeated dosing can maintain exposure, while prolonged infusion may improve time above a pharmacologic threshold without increasing peak toxicity. Therapeutic drug monitoring may be useful for selected agents, but plasma concentrations remain an imperfect surrogate for tissue exposure.

Combination strategies can modify the tumor microenvironment. Vascular normalization may improve perfusion and reduce abnormal pressure when carefully dosed, although excessive vascular pruning can worsen delivery. Enzymatic degradation of hyaluronic acid, stromal modulation, reduction of fibrosis, and approaches targeting cancer-associated fibroblasts have been investigated to increase interstitial transport. These interventions require caution because the stroma can also restrain invasion, and broad disruption may increase dissemination or inflammation.

Local delivery can bypass some systemic barriers. Intratumoral injection, convection-enhanced delivery, implantable depots, regional perfusion, and intraperitoneal administration may produce high local concentrations while limiting systemic exposure. However, distribution after local administration depends on injection pressure, tissue geometry, leakage, catheter placement, and the presence of septations or necrosis. Such methods are most effective when delivery can be accurately targeted and monitored. Standard systemic therapy remains necessary when microscopic disease exists outside the treated compartment.

Recent Advances / Emerging Therapies

Nanomedicine is being developed to improve solubility, protect labile payloads, extend circulation, and enable controlled release. Liposomes, polymeric nanoparticles, albumin-based carriers, and stimuli-responsive systems can be functionalized with ligands for tumor-associated receptors. Nevertheless, successful clinical translation requires more than increased tumor accumulation; carriers must penetrate beyond vessels, release active drug, and avoid sequestration by the reticuloendothelial system. Antibody–drug conjugates provide selective delivery but may encounter binding-site barriers and heterogeneous antigen expression.

Emerging platforms include bispecific constructs, tumor-activated prodrugs, extracellular-vesicle-based carriers, and agents responsive to acidity, proteases, enzymes, or redox conditions. Focused ultrasound, including blood–brain barrier modulation, is being studied to increase regional delivery. Electroporation, thermal ablation, and implantable hydrogel systems may enhance local transport or provide sustained release. Artificial intelligence and mechanistic computational models are increasingly used to integrate imaging, pharmacokinetics, tissue architecture, and treatment response, potentially supporting patient-specific delivery predictions.

Immunotherapy adds another dimension. Distribution of immune checkpoint inhibitors, cytokines, cellular therapies, and bispecific T-cell engagers depends not only on drug penetration but also on immune-cell trafficking and spatial organization. Strategies that improve vascular access or reduce immunosuppressive stromal signaling may increase both therapeutic exposure and immune engagement. Future trials should include tissue pharmacology, spatial biomarkers, and clinically meaningful measures of target engagement rather than relying exclusively on systemic pharmacokinetic data.

Guideline Recommendations

Current oncology guidelines generally recommend treatment according to tumor type, stage, molecular characteristics, organ function, performance status, and validated clinical evidence; they do not yet provide universal dosing algorithms based directly on intratumoral concentration. Clinicians should nevertheless consider tissue penetration when treating pharmacologically protected sites such as the central nervous system, bulky necrotic disease, and heavily fibrotic tumors. Therapy should be selected using approved indications and evidence from well-designed trials, with attention to organ-specific pharmacology and known sanctuary compartments.

When response is discordant, clinicians should evaluate adherence, exposure, drug interactions, pharmacogenomic factors, target alteration, clonal evolution, and distribution barriers before labeling a tumor intrinsically resistant. Multidisciplinary review involving medical oncology, radiology, pathology, pharmacology, and interventional specialists can help determine whether biopsy, functional imaging, regional treatment, or a change in mechanism is appropriate. Experimental delivery technologies should be used within ethically approved clinical studies with clear monitoring of toxicity, local complications, and systemic escape.

Conclusion

Intratumoral drug distribution is a central link between administered dose and therapeutic effect in solid tumors. Abnormal vasculature, elevated interstitial pressure, extracellular matrix density, heterogeneous perfusion, cellular uptake, and intracellular trafficking collectively determine whether malignant cells receive an effective exposure. Clinical failure may therefore reflect spatial underdosing even when plasma pharmacokinetics and target expression appear favorable. Improved management requires integration of tumor biology, quantitative imaging, tissue pharmacology, pharmacodynamic biomarkers, and patient-specific treatment planning. Nanocarriers, local delivery, microenvironment modulation, focused ultrasound, and computational modeling offer promising solutions, but their value must be confirmed through rigorous clinical studies. A distribution-aware approach to drug development and cancer care has the potential to reduce therapeutic resistance, improve response durability, and make treatment selection more precise.